<DOC>
	<DOC>NCT00849316</DOC>
	<brief_summary>This study is conducted in Asia. The aim of this observational study is to investigate the clinical safety profile and effectiveness while using SC NovoRapid™ (insulin aspart) in patients with coexisting diabetes and kidney disease under normal clinical practice conditions in India.</brief_summary>
	<brief_title>Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Any subject with coexisting kidney disease and type 1 or type 2 diabetes is eligible for the study, including: newlydiagnosed subjects, insulin naïve and subjects who have received insulin or an insulin analogue before Subjects with kidney disease (stage IIV) including transplant patients will be eligible for the study, if initiated with NovoRapid™" Subjects who are unlikely to comply with protocol requirements, e.g., uncooperative attitude, inability to return for the final visit Subjects with stage V of chronic kidney disease Subjects who previously enrolled in this study Known or suspected allergy to trial product(s) or related products</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>